Do analysts rate CABR or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CABR or JUNS more profitable?

Caring Brands' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Caring Brands N/A N/A N/A Jupiter Neurosciences N/A -1,314.62% -228.63%

Do analysts rate JUNS or GRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is JUNS or GRTX more profitable?

Galera Therapeutics' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -228.63% Galera Therapeutics N/A N/A -99.34%

Does the media refer more to JUNS or GRTX?

In the previous week, Jupiter Neurosciences had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 1 mentions for Galera Therapeutics. Jupiter Neurosciences' average media sentiment score of 0.11 beat Galera Therapeutics' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate COCP or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is COCP or JUNS more profitable?

Cocrystal Pharma's return on equity of -150.61% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Jupiter Neurosciences N/A -1,314.62% -228.63%

Does the media prefer COCP or JUNS?

In the previous week, Jupiter Neurosciences had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 3 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.33 beat Jupiter Neurosciences' score of 0.11 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ELOX or JUNS?

Eloxx Pharmaceuticals currently has a consensus target price of $41.50, suggesting a potential upside of 136.20%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELOX or JUNS more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Jupiter Neurosciences N/A -1,314.62% -228.63%

Do analysts recommend CALC or JUNS?

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 1,354.55%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CALC or JUNS more profitable?

CalciMedica's return on equity of -863.40% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Jupiter Neurosciences N/A -1,314.62% -228.63%

Does the media prefer CALC or JUNS?

In the previous week, Jupiter Neurosciences had 4 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 1 mentions for CalciMedica. Jupiter Neurosciences' average media sentiment score of 0.11 beat CalciMedica's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Jupiter Neurosciences (JUNS) Competitors

$5.10 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.36 +0.27 (+5.20%)

As of 08/7/2026 07:59 PM Eastern

Compare

JUNS vs. CABR, GRTX, COCP, ELOX, and CALC

Should you buy Jupiter Neurosciences stock or one of its competitors? MarketBeat compares Jupiter Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jupiter Neurosciences include Caring Brands (CABR), Galera Therapeutics (GRTX), Cocrystal Pharma (COCP), Eloxx Pharmaceuticals (ELOX), and CalciMedica (CALC). These companies are all part of the "pharmaceuticals" industry.

How does Jupiter Neurosciences compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Caring Brands has higher earnings, but lower revenue than Jupiter Neurosciences. Caring Brands is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	N/A	N/A	-$6.28M	-$0.64	N/A
Jupiter Neurosciences	$20K	122.40	-$8.65M	-$20.30	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jupiter Neurosciences had 5 more articles in the media than Caring Brands. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 0 mentions for Caring Brands. Jupiter Neurosciences' average media sentiment score of 0.11 beat Caring Brands' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Caring Brands	Neutral
Jupiter Neurosciences	Neutral

Caring Brands' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	N/A	N/A
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Summary

Caring Brands and Jupiter Neurosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Galera Therapeutics?

Jupiter Neurosciences (NASDAQ:JUNS) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Jupiter Neurosciences has higher revenue and earnings than Galera Therapeutics. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	122.40	-$8.65M	-$20.30	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Galera Therapeutics' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
Galera Therapeutics	N/A	N/A	-99.34%

50.8% of Galera Therapeutics shares are owned by institutional investors. 38.6% of Jupiter Neurosciences shares are owned by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Jupiter Neurosciences has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.6, indicating that its stock price is 160% more volatile than the broader market.

In the previous week, Jupiter Neurosciences had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 1 mentions for Galera Therapeutics. Jupiter Neurosciences' average media sentiment score of 0.11 beat Galera Therapeutics' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jupiter Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jupiter Neurosciences beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Cocrystal Pharma's return on equity of -150.61% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.7% of Cocrystal Pharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jupiter Neurosciences has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Jupiter Neurosciences	$20K	122.40	-$8.65M	-$20.30	N/A

In the previous week, Jupiter Neurosciences had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 3 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.33 beat Jupiter Neurosciences' score of 0.11 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cocrystal Pharma has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Summary

Cocrystal Pharma beats Jupiter Neurosciences on 6 of the 11 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Eloxx Pharmaceuticals currently has a consensus target price of $41.50, suggesting a potential upside of 136.20%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Jupiter Neurosciences had 5 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 0 mentions for Eloxx Pharmaceuticals. Jupiter Neurosciences' average media sentiment score of 0.11 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Jupiter Neurosciences	Neutral

Eloxx Pharmaceuticals has a beta of -1863.11, suggesting that its stock price is 186,411% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

Eloxx Pharmaceuticals has higher revenue and earnings than Jupiter Neurosciences. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	1.91	-$5.99M	-$15.29	N/A
Jupiter Neurosciences	$20K	122.40	-$8.65M	-$20.30	N/A

Summary

Eloxx Pharmaceuticals beats Jupiter Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Jupiter Neurosciences compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

CalciMedica's return on equity of -863.40% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 1,354.55%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Jupiter Neurosciences	$20K	122.40	-$8.65M	-$20.30	N/A

CalciMedica has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

In the previous week, Jupiter Neurosciences had 4 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for Jupiter Neurosciences and 1 mentions for CalciMedica. Jupiter Neurosciences' average media sentiment score of 0.11 beat CalciMedica's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CalciMedica and Jupiter Neurosciences tied by winning 6 of the 12 factors compared between the two stocks.

Get Jupiter Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JUNS vs. The Competition

Export

Metric	Jupiter Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.45M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-0.25	790.97	270.59	25.05
Price / Sales	122.40	739.02	599.41	84.35
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	-1.28	10.28	11.21	6.43
Net Income	-$8.65M	$2.78B	$3.45B	$348.10M
7 Day Performance	-32.00%	2.74%	3.41%	2.68%
1 Month Performance	-64.19%	-0.66%	-0.71%	-0.83%
1 Year Performance	-94.38%	192.51%	77.31%	23.97%

Jupiter Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JUNS Jupiter Neurosciences	0.999 of 5 stars	$5.10 flat	N/A	-94.4%	$2.45M	$20K	N/A	5	Analyst Downgrade Gap Up
CABR Caring Brands	0.5122 of 5 stars	$1.56 flat	N/A	N/A	$14.18M	N/A	N/A	4	Gap Up
GRTX Galera Therapeutics	N/A	$0.09 flat	N/A	+282.6%	$14.12M	N/A	N/A	30	Upcoming Earnings
COCP Cocrystal Pharma	1.1126 of 5 stars	$1.02 +4.1%	N/A	-34.6%	$13.51M	N/A	N/A	10	Upcoming Earnings Gap Up
ELOX Eloxx Pharmaceuticals	1.8445 of 5 stars	$17.53 -4.9%	$41.50 +136.7%	N/A	$12.69M	$6.36M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JUNS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. CABR, GRTX, COCP, ELOX, and CALC

How does Jupiter Neurosciences compare to Caring Brands?

Summary

How does Jupiter Neurosciences compare to Galera Therapeutics?

Summary

How does Jupiter Neurosciences compare to Cocrystal Pharma?

Summary

How does Jupiter Neurosciences compare to Eloxx Pharmaceuticals?

Summary

How does Jupiter Neurosciences compare to CalciMedica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. CABR, GRTX, COCP, ELOX, and CALC

How does Jupiter Neurosciences compare to Caring Brands?

Which has preferable valuation and earnings, CABR or JUNS?

Do analysts rate CABR or JUNS?

Does the media prefer CABR or JUNS?

Is CABR or JUNS more profitable?

Summary

How does Jupiter Neurosciences compare to Galera Therapeutics?

Which has stronger earnings & valuation, JUNS or GRTX?

Is JUNS or GRTX more profitable?

Do institutionals & insiders hold more shares of JUNS or GRTX?

Do analysts rate JUNS or GRTX?

Which has more risk and volatility, JUNS or GRTX?

Does the media refer more to JUNS or GRTX?

Summary

How does Jupiter Neurosciences compare to Cocrystal Pharma?

Is COCP or JUNS more profitable?

Do analysts rate COCP or JUNS?

Do institutionals and insiders have more ownership in COCP or JUNS?

Which has stronger earnings & valuation, COCP or JUNS?

Does the media prefer COCP or JUNS?

Which has more risk & volatility, COCP or JUNS?

Summary

How does Jupiter Neurosciences compare to Eloxx Pharmaceuticals?

Is ELOX or JUNS more profitable?

Do analysts recommend ELOX or JUNS?

Do institutionals & insiders hold more shares of ELOX or JUNS?

Does the media refer more to ELOX or JUNS?

Which has more risk and volatility, ELOX or JUNS?

Which has stronger valuation and earnings, ELOX or JUNS?

Summary

How does Jupiter Neurosciences compare to CalciMedica?

Is CALC or JUNS more profitable?

Do analysts recommend CALC or JUNS?

Which has better valuation and earnings, CALC or JUNS?

Which has more risk and volatility, CALC or JUNS?

Does the media prefer CALC or JUNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools